Written By | Health News Agencies
Families of children with MCT8 deficiency have waited 80 years since doctors first described the condition
Search
WASHINGTON / STOCKHOLM
Imagine a house where the heating is cranked so high the walls are sweating, while the one room that matters most, the nursery, stays freezing cold. That, in plain words, is what happens inside the body of a child born with MCT8 deficiency.
The thyroid hormone that every brain needs to grow and wire itself up is pumping round the bloodstream in huge amounts. It just can't get through the door into the brain. So the brain goes hungry while the rest of the body, the heart, the muscles, the liver, is flooded and overworked.
On Monday 28 September 2026 the US Food and Drug Administration approved the first medicine ever for this rare and devastating condition. It is called Emcitate, its active ingredient is tiratricol, and it is made by Swedish company Egetis Therapeutics.
"Until now, patients living with MCT8 deficiency and their families had no FDA-approved treatment option," said Dr Marina Zemskova, deputy director of the Division of General Endocrinology at the FDA's drug centre.
For the handful of families across America who live with the disease every day, it is a genuine turning point. But this is a story with an important catch, and anyone reading the headlines should understand exactly what this drug can, and cannot, do.
THE DISEASE WITH A BROKEN DOOR
MCT8 deficiency is also known as Allan-Herndon-Dudley syndrome, after the doctors who first described affected families in the 1940s. It is caused by faulty copies of a gene called SLC16A2, which sits on the X chromosome. That is why it overwhelmingly strikes boys: girls usually carry a second, working copy of the X chromosome that protects them.
The gene holds the instructions for a protein called MCT8, a tiny transporter on the surface of cells. Think of it as a doorman. Its job is to wave thyroid hormone through into cells, and crucially into the brain, across the tightly guarded blood-brain barrier.
When MCT8 doesn't work, two things go wrong at once.
First, the brain is starved of thyroid hormone at exactly the time it needs it most, in the womb and early childhood. According to the FDA, many patients can never walk or even sit up on their own. Many have no speech at all, or only a few words. They have intellectual disability and struggle to feed.
Second, the active form of thyroid hormone, known as T3, piles up in the blood. Doctors call this peripheral thyrotoxicosis, meaning the body outside the brain is being poisoned by too much hormone. It keeps the body in a constant revved-up state: a racing heart, raised blood pressure, muscle wasting, poor weight gain and a greater risk of infections.
Egetis says patients have a reported median life expectancy of about 35 years, and the company believes the constant hormone overload plays a big part in that early death.
THE DRUG THAT DOESN'T NEED THE DOORMAN
The cleverness of tiratricol is that it doesn't need MCT8 to get in.
"The challenge in treating MCT8 deficiency has always been that the protein needed to deliver thyroid hormone into cells is the one that isn't working," explained Dr Hylton Joffe, who directs the FDA office covering cardiology, hematology, endocrinology and nephrology. "This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels."
Tiratricol, sometimes called Triac, is a close chemical cousin of the body's own thyroid hormone. It switches on the same thyroid hormone receptors. Because it can get into cells by a different route, it can signal to the body's hormone control centre, the hypothalamus and pituitary gland, that there is enough thyroid hormone around. The control centre then eases off, and the flood of T3 in the blood falls.
The medicine comes as tablets that are dissolved into a liquid and taken once a day, either swallowed or given through a feeding tube. That matters enormously for children who cannot swallow tablets safely.
WHAT THE TRIALS SHOWED
The FDA said it based its decision on two studies in patients ranging from babies to adults: an international, randomised, placebo-controlled trial and a longer, open-label study where everyone got the drug.
The earlier, landmark study, known as Triac Trial I, was led by researchers at Erasmus Medical Center in Rotterdam and published in The Lancet Diabetes & Endocrinology in 2019. In that single-arm trial, blood T3 levels fell from an average of 4.97 nanomoles per litre at the start to 1.82 after 12 months, a drop of well over half. Resting heart rate fell by about nine beats a minute.
The key controlled trial, called ReTRIACt, used an unusual design. Boys aged four and over who were already stable on tiratricol were randomly split into two groups. One group carried on with the drug. The other was switched, without anyone knowing, to a dummy medicine for up to 30 days, or until their T3 climbed above the normal range.
The result was stark. All eight boys switched to placebo saw their T3 levels rise, by between 0.49 and 2.08 nanomoles per litre. Every one of those rises was bigger than any change seen in the seven boys who stayed on the drug, whose levels moved between minus 0.24 and plus 0.40. The difference was statistically significant, with a p-value of 0.034.
In plain English: take the drug away and the hormone flood comes straight back.
Across both studies, the FDA said, patients on Emcitate had lower thyroid hormone levels in the blood and improvements in the heart and metabolism, including lower systolic blood pressure and heart rate.
THE BIG CATCH: IT DOESN'T FIX THE BRAIN
Here is the part that the celebratory headlines tend to skip.
Emcitate is approved specifically to treat "peripheral thyrotoxicosis", the overload in the body. It is not approved to treat the brain problems that make this disease so devastating, and there is no proof yet that it can.
In a second study, Triac Trial II, which enrolled young boys, children on tiratricol did show some numerical gains in gross motor skills, the ability to control their bodies. But according to the medical publication Contemporary Pediatrics, those gains did not reach statistical significance when compared with historical records of untreated children. The T3 reductions, on the other hand, lasted in every patient.
Whether starting the drug in the first weeks of life, before brain damage is done, could change a child's development remains an open question.
The evidence base is also small. The pivotal randomised trial rested on a blood test, measured over just 30 days, in only 15 patients. For a disease this rare, experts say that is not surprising, but it does mean long-term follow-up will be watched closely.
SIDE EFFECTS AND WARNINGS
The most common side effects in the trials were diarrhoea, vomiting, rash and excessive sweating.
Because tiratricol acts like thyroid hormone, patients can get signs of too much of it, especially when they first start or when the dose is being adjusted. The label lists a faster heart rate, higher blood pressure, diarrhoea, heavy sweating, irritability, sleeplessness and nightmares. Doctors are told to monitor patients and adjust the dose.
There is also a quirk for doctors: tiratricol can confuse some standard blood tests for T3, making results unreliable and overestimating levels.
The drug must not be used by people with an overactive thyroid for other reasons, is not recommended for ordinary underactive thyroid, and should not be combined with other thyroid medicines without medical advice.
And the label carries the FDA's most serious type of warning, a boxed warning, stating in capital letters that it is NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS. That warning is there for good reason. Thyroid-type hormones speed up the metabolism, and tiratricol has a murky past: years ago it turned up in so-called "fat-burning" supplements, and federal regulators warned the public against them. This medicine is for a specific, serious genetic disease, full stop.
EXPERT PERSPECTIVE
Dr Andrew Bauer, a paediatric endocrinologist and principal investigator in both ReTRIACt and Triac Trial II, said: "Through my experience caring for patients with MCT8 deficiency, I have seen firsthand the profound impact this complex and life-limiting disorder can have on patients and their families. Early diagnosis is critical so that patients can be appropriately evaluated, connected with specialists and receive coordinated multidisciplinary care."
He added that the approval "provides physicians in the United States with the first approved treatment option for patients and represents an important advance for the MCT8 deficiency community."
Patient group the MCT8-AHDS Foundation called the decision "a historic milestone" and "a testament to what is possible when a community comes together with a shared commitment to advancing care."
Egetis chief executive Nicklas Westerholm said: "Today marks a turning point for patients living with MCT8 deficiency and their caregivers, who have waited long for an approved treatment in the United States. Our immediate focus is ensuring that eligible patients can access EMCITATE as quickly as possible."
Independent reviewers are more measured. Contemporary Pediatrics, in its analysis of the approval, stressed that the indication "targets peripheral thyrotoxicosis, not the neurologic manifestations that drive most of the disease burden", and urged clinicians to read the full prescribing information before starting treatment.
The FDA gave the drug almost every fast-lane label it has: Orphan Drug, Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations, plus Priority Review. That shows how seriously regulators took the unmet need.
THE MONEY BEHIND THE MEDICINE
Egetis, which is listed on the Nasdaq Stockholm exchange, already sells Emcitate in the European Union. The US approval is a huge moment for the small company.
Alongside the approval, the FDA handed Egetis a Rare Pediatric Disease Priority Review Voucher, a golden ticket that lets its holder speed another drug through FDA review. These vouchers can be sold to bigger drugmakers, and have fetched well over $100 million apiece in recent years. Egetis says it is exploring a sale, possibly in the last three months of 2026.
The company has not yet announced a US price.
WHAT THIS MEANS FOR YOU
For most readers, MCT8 deficiency is a disease they will never encounter. But if you are a parent of a boy with unexplained severe developmental delay, especially poor head control, inability to sit, or no speech, alongside a thin build and a fast heart rate, this approval is worth knowing about.
The key clue can be a surprising pattern on routine thyroid blood tests: high T3 with low or low-normal T4 and a normal or slightly raised TSH. That odd combination should prompt a doctor to think about MCT8 deficiency and order genetic testing.
If your family is already living with the condition, here is what to expect:
Timing: Egetis says Emcitate should be commercially available in the US within eight to ten weeks of approval, so around late November to early December 2026.
Access help: the company has set up a patient support programme called Egetis RareLink, working with specialty pharmacy PANTHERx Rare. Families and doctors can call 1-844-4EGETIS (1-844-434-3847).
Realistic hopes: the drug is designed to calm the heart, blood pressure and metabolic strain caused by too much hormone in the body. It has not been shown to restore walking, speech or learning. Talk frankly with your specialist about goals.
Monitoring: expect regular check-ups, heart rate and blood pressure checks, and careful dose adjustments, particularly at the start. Remember that T3 blood tests may be unreliable on this drug, so your team may use other markers.
Other medicines: do not combine it with other thyroid medicines unless your doctor specifically tells you to.
CONCLUSION
For eight decades, families of boys with MCT8 deficiency have been told there was nothing specific to offer. On Monday that changed.
Emcitate will not give these children back the brain development the disease took from them. But by turning down the relentless hormonal overdrive that wears out their hearts and bodies, it may give them healthier, more comfortable, and perhaps longer lives.
The science behind it is elegant: a molecule that simply walks round a locked door. The evidence is still thin, and the biggest question, whether treating early enough could protect the growing brain, remains unanswered.
For now, a community that has spent generations waiting finally has something in the medicine cabinet. As the MCT8-AHDS Foundation put it, it is "an important step toward ensuring patients have access to a treatment." The next step is proving how far that treatment can go.
